Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in Advanced Gastric or Esophageal Cancer
NCT04945733Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in gastric cancer (GC), esophageal cancer, sponsored by Janssen Pharmaceutical. Started Aug 2021; status: terminated.
02
Drugs
amivantamab
03
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT04945733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945733.